Sarclisa approved in EU for adults new to MM and transplant ineligible
Regulators in the European Union (EU) have approved…
Myeloma
Latest news
AbbVie, Simcere Zaiming partner on myeloma treatment SIM0500
Abbvie is teaming up with China-based company…
Under-the-skin Sarclisa found as effective as approved formulation
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab)…
Minimal residual disease is potential early outcome measure in myeloma
Minimal residual disease or MRD — defined as a…
Cell therapy anito-cel shows promise for hard-to-treat RRMM
Most people with relapsed or refractory multiple myeloma…
Carvykti delays myeloma symptom worsening, per Phase 3 trial data
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier…
